Clinical Trials Logo

Refractory clinical trials

View clinical trials related to Refractory.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05911321 Recruiting - Multiple Myeloma Clinical Trials

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting has not been approved by the Food and Drug Administration (FDA).

NCT ID: NCT05153330 Recruiting - Cancer Clinical Trials

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

NCT ID: NCT03881774 Recruiting - B Cell Lymphoma Clinical Trials

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells

NCT ID: NCT03881761 Recruiting - Refractory Clinical Trials

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Start date: February 1, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

NCT ID: NCT03275493 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Start date: July 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic leukemia patients.

NCT ID: NCT02407275 Recruiting - Chronic Disease Clinical Trials

Rhinosinusites Chroniques

Start date: February 2015
Phase: N/A
Study type: Interventional

To analyse and describe sinus microbiota, during hard to treat (or refractory) rhinosinusitis, using culturomic and metagenomic methods (i.e. to culture on many different medium of culture to grow hard to cultivate bacteria + to sequence and analyse all DNA contained in samples). Samples are middle meatus swabs or pus aspiration, done during usually patient following.